These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 25384218)
1. RASAL2 activates RAC1 to promote triple-negative breast cancer progression. Feng M; Bao Y; Li Z; Li J; Gong M; Lam S; Wang J; Marzese DM; Donovan N; Tan EY; Hoon DS; Yu Q J Clin Invest; 2014 Dec; 124(12):5291-304. PubMed ID: 25384218 [TBL] [Abstract][Full Text] [Related]
2. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Yan M; Li X; Tong D; Han C; Zhao R; He Y; Jin X Oncol Rep; 2016 Jul; 36(1):65-71. PubMed ID: 27108696 [TBL] [Abstract][Full Text] [Related]
3. RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Hui K; Gao Y; Huang J; Xu S; Wang B; Zeng J; Fan J; Wang X; Yue Y; Wu S; Hsieh JT; He D; Wu K Cell Death Dis; 2017 Feb; 8(2):e2600. PubMed ID: 28182001 [TBL] [Abstract][Full Text] [Related]
4. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. McLaughlin SK; Olsen SN; Dake B; De Raedt T; Lim E; Bronson RT; Beroukhim R; Polyak K; Brown M; Kuperwasser C; Cichowski K Cancer Cell; 2013 Sep; 24(3):365-78. PubMed ID: 24029233 [TBL] [Abstract][Full Text] [Related]
5. Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway. Fan D; Yu S; Yang Y; Qu S Biol Pharm Bull; 2021; 44(7):992-998. PubMed ID: 34193694 [TBL] [Abstract][Full Text] [Related]
6. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046 [TBL] [Abstract][Full Text] [Related]
7. PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy. Bao Y; Qian C; Liu MY; Jiang F; Jiang X; Liu H; Zhang Z; Sun F; Fu N; Hou Z; Ke Y; Li Y; Qian ZM Autophagy; 2021 Nov; 17(11):3607-3621. PubMed ID: 33563064 [TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Rasal2 facilitates breast cancer progression. Wang X; Qian C; Yang Y; Liu MY; Ke Y; Qian ZM EBioMedicine; 2019 Dec; 50():144-155. PubMed ID: 31759919 [TBL] [Abstract][Full Text] [Related]
9. RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis. Huang Y; Zhao M; Xu H; Wang K; Fu Z; Jiang Y; Yao Z Oncotarget; 2014 Aug; 5(16):6734-45. PubMed ID: 25216515 [TBL] [Abstract][Full Text] [Related]
10. RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition. Li N; Li S Biochem Biophys Res Commun; 2014 Dec; 455(3-4):358-62. PubMed ID: 25446096 [TBL] [Abstract][Full Text] [Related]
11. miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer. Xiong J; Xing S; Dong Z; Niu L; Xu Q; Li Y; Liu P; Yang P Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300072 [TBL] [Abstract][Full Text] [Related]
12. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785 [TBL] [Abstract][Full Text] [Related]
13. RASAL2 Plays Inconsistent Roles in Different Cancers. Zhou B; Zhu W; Jiang X; Ren C Front Oncol; 2019; 9():1235. PubMed ID: 31799194 [TBL] [Abstract][Full Text] [Related]
14. Rasal2 deficiency reduces adipogenesis and occurrence of obesity-related disorders. Zhu X; Xie S; Xu T; Wu X; Han M Mol Metab; 2017 Jun; 6(6):494-502. PubMed ID: 28580280 [TBL] [Abstract][Full Text] [Related]
15. Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Olsen SN; Wronski A; Castaño Z; Dake B; Malone C; De Raedt T; Enos M; DeRose YS; Zhou W; Guerra S; Loda M; Welm A; Partridge AH; McAllister SS; Kuperwasser C; Cichowski K Cancer Discov; 2017 Feb; 7(2):202-217. PubMed ID: 27974415 [TBL] [Abstract][Full Text] [Related]
16. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Yue Y; Wu K; Qian W; Zhu Z; Zhang S; Zhang W; Zhang W; Wu S; Li L; Wu Z; Ma Q; Xie K; Wang Z Int J Biol Sci; 2022; 18(10):4245-4259. PubMed ID: 35844783 [TBL] [Abstract][Full Text] [Related]
17. Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. Sears R; Gray JW Cancer Discov; 2017 Feb; 7(2):131-133. PubMed ID: 28167613 [TBL] [Abstract][Full Text] [Related]
18. Brain endothelial cells promote breast cancer cell extravasation to the brain via EGFR-DOCK4-RAC1 signalling. Galloni C; Egnuni T; Zahed Mohajerani S; Ye J; Mittnacht S; Speirs V; Lorger M; Mavria G Commun Biol; 2024 May; 7(1):602. PubMed ID: 38762624 [TBL] [Abstract][Full Text] [Related]
19. ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells. Lewis-Saravalli S; Campbell S; Claing A Cell Signal; 2013 Sep; 25(9):1813-9. PubMed ID: 23707487 [TBL] [Abstract][Full Text] [Related]
20. Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells. Koh MS; Moon A Biochem Biophys Res Commun; 2011 Mar; 406(1):25-9. PubMed ID: 21281602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]